Oleanolic acid derivative immunologic adjuvant and application thereof

By modifying the structure of QS-21, the synthesis of oleanolic acid derivative immune adjuvant is solved, and the use restriction caused by QS-21 is achieved due to its complex structure and instability is achieved, and a more stable and efficient immune adjuvant is achieved. It is better than QS-21's anti-hemolytic effect.

CN119019485AInactive Publication Date: 2024-11-26BEIJING UNIV OF CHEM TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310585542.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Due to the complex structure, chemical instability and adverse hemolytic effects of QS-21 immune adjuvant, it is limited in human use, and it is difficult to obtain samples, and the mechanism of action has not been fully elucidated.

Method used

By designing and modifying the four domains of QS-21, convenient oleanolic acid derivative immune adjuvants are synthesized and prepared, including the introduction of carbonyl groups at the C3 position and the introduction of hydroxy groups at the C2 position, and the reconstruction of trisaccharide and tetrasaccharide structures. The polychiral acyl chain is modified and the ester moiety is replaced with amide bonds, simplifying the structure and improving stability.

Benefits of technology

The synthetic route of oleanolic acid derivative immune adjuvants has been shortened, structure simplified and stability improved, and the anti-hemolytic effect is better than QS-21, providing a more feasible alternative to immune adjuvants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019485A_ABST
    Figure CN119019485A_ABST
Patent Text Reader

Abstract

The invention discloses an oleanolic acid derivative immunologic adjuvant and application thereof, and belongs to the field of immune and vaccine adjuvants. According to the invention, immunostimulatory oleanane type triterpenoid saponin QS-21 is designed and transformed, four structural domains of the QS-21, namely a triterpenoid unit, a trisaccharide and tetrasaccharide structure and an acyl side chain, are respectively designed and synthesized, and all fragments are connected to synthesize the oleanolic acid derivative. According to the method, oleanolic acid is taken as a raw material, carbonyl and oxime functional groups are introduced to the C3 position, and hydroxyl is introduced to the C2 position; branched trisaccharide is reconstructed and optimized, low-price sugar molecules such as glucose, cellobiose and maltotriose are used for replacement, tetrasaccharide fragments are tried to be cut off, and synthesis steps are shortened; a multi-chiral center acyl chain is modified, a sugar chain is introduced to the tail end of the acyl chain, an ester part connected with a sugar unit is replaced with an amido bond structure, the structure is simplified, the stability is improved, and finally all fragments are connected. Experiments prove that the preparation method is reasonable, economical and efficient. According to the invention, the hemolytic activity of the synthesized oleanolic acid derivative is studied by taking QS-21 as a contrast, and the anti-hemolytic activity of the derivative is superior to that of QS-21 through calculation of the hemolysis rate, so that the derivative has important application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of immunity and vaccine adjuvants, and in particular relates to oleanolic acid derivative immune adjuvants and applications thereof. Background Art

[0002] QS-21, as an immunostimulatory oleanane-type triterpenoid saponin, is widely used in various vaccine clinical studies due to its significant adjuvant efficacy. However, due to some limiting factors, including structural complexity, scarcity, chemical instability, severe immune side effects, expensive and limited intellectual property procurement, dose-limiting toxicity and adverse hemolytic effects, its use in humans is still limited. In addition, it is difficult to obtain samples, and its mechanism of action remains to be elucidated. The present invention discloses a method for chemically synthesizing oleanolic acid derivatives as immunoadjuvants using oleanolic acid as a raw material, and the synthesis route is short, so the invention has important application value.

[0003] Summary of the invention

[0004] The technical problem to be solved by the present invention is to provide a method for synthesizing oleanolic acid derivative immune adjuvants in view of the limiting factors such as the complex structure, chemical instability, and adverse hemolytic effect of the above-mentioned QS-21 immune adjuvant.

[0005] The objective of the present invention is achieved through the following technical solutions:

[0006] A method for synthesizing an oleanolic acid derivative immunoadjuvant, characterized in that the four structural domains of the QS-21 immunoadjuvant, namely the triterpene unit, the trisaccharide and tetrasaccharide structures, and the acyl side chain, are designed and modified to synthesize an oleanolic acid derivative immunoadjuvant that is convenient to prepare. The method comprises the following steps:

[0007] (1) Using oleanolic acid as a raw material, a carbonyl group and an oxime functional group were introduced at the C3 position, and a hydroxyl group was introduced at the C2 position to design and synthesize fragment A;

[0008] (2) Reconstruct and optimize the branched trisaccharides and bridged linear tetrasaccharides by replacing them with inexpensive sugar molecules such as glucose, cellobiose, and maltotriose, and try to remove the tetrasaccharide fragments to shorten the synthesis steps, that is, design and synthesize the B and C fragments;

[0009] (3) Modify the complex multi-chiral central acyl chain by introducing glucose, cellobiose, and maltotriose at the end of the acyl chain and replace the ester part connected to the sugar unit with an amide bond structure to simplify the structure and improve the stability, that is, design and synthesize the D fragment;

[0010] (4) Connect the fragments to synthesize oleanolic acid derivatives.

[0011]

[0012] Preferably, the structural formula of the oleanolic acid derivative is:

[0013]

[0014]

[0015] Compared with the prior art, the present invention has the following advantages:

[0016] In the present invention, the oleanolic acid derivative immunoadjuvant has a shortened synthesis route, a simplified structure and improved stability. Through the hemolytic experiment, it is shown that the anti-hemolytic effect of the oleanolic acid derivative immunoadjuvant is better than that of the QS-21 immunoadjuvant. The synthetic route of the oleanolic acid derivative immunoadjuvant L1 of the present invention is as follows:

[0017]

[0018] The synthesis method of the oleanolic acid derivative immunoadjuvant L1 of the present invention comprises the following steps:

[0019] Steps: Oleanolic acid is dissolved in dry DCM, oxalyl chloride is slowly added dropwise at room temperature, the reaction solution is evaporated for 4 hours, toluene is added to dissolve and then evaporated, and the solvent is removed three times. The above solid product is dissolved in anhydrous DCM solution, 5-amino-1-pentanol raw material D1 and triethylamine are added, and the reaction is carried out at room temperature to obtain oleanolic acid-28-acyl-pentanol.

[0020] The synthesis method of the oleanolic acid derivative immune adjuvants L10, L17 and L19 of the present invention is the same as that of L1.

[0021] The synthetic route of the oleanolic acid derivative immunoadjuvant L2 of the present invention is as follows:

[0022]

[0023] The method for synthesizing the oleanolic acid derivative immunoadjuvant L2 of the present invention comprises the following steps:

[0024] Step 1): Add the raw material D1 to (Boc)2O, and react at 80°C for 10 min to obtain tert-butyl (5-hydroxypentyl)carbamate (D10);

[0025] Step 2): tert-butyl (5-hydroxypentyl)carbamate, glucose trichloroacetimidate B4, The molecular sieves were dissolved in dry DCM, stirred at room temperature for 0.5 h, the temperature was lowered to 0°C, TMSOTf was slowly added dropwise, and stirring was continued at room temperature for 2 h to obtain tert-butyl (5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)carbamate (D11);

[0026] Step 3): dissolve the tert-butyl (5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)carbamate obtained in step 2) in dichloromethane, add trifluoroacetic acid, and stir at room temperature for 1 hour to obtain 5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentane-1-amine (D14);

[0027] Step 4): Oleanolic acid is dissolved in anhydrous dichloromethane, oxalyl chloride is slowly added dropwise at room temperature, stirred for 4 hours, the reaction solution is evaporated to dryness, toluene is added to dissolve and evaporated to dryness again, and the solvent is removed three times. The above solid product is dissolved in anhydrous DCM solution, 5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentane-1-amine and triethylamine obtained in step 3) are added, and the mixture is stirred at room temperature for 4 hours to obtain oleanolic acid-28-acyl-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentane) (F2);

[0028] Step 5): Dissolve the oleanolic acid-28-acyl-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentane) obtained in step 4) in dry DCM / MeOH, add freshly prepared sodium methoxide:methanol solution, and stir at room temperature for 2h to obtain oleanolic acid-28-acyl-(5-β-D-glucose)oxy)pentane) (L2).

[0029] The synthesis method of the oleanolic acid derivative immunoadjuvants L3-L5 and L11-L13 of the present invention is the same as L2. Glucose trichloroacetimidate B4 is replaced by cellobiose trichloroacetimidate C4 and maltotriose trichloroacetimidate C7 to synthesize them. The synthesis route of the oleanolic acid derivative immunoadjuvant L7 of the present invention is as follows:

[0030]

[0031] The method for synthesizing the oleanolic acid derivative immunoadjuvant L7 of the present invention comprises the following steps:

[0032] Step 1): Dissolve the raw materials D17 and (Boc)2O in a mixed solution of acetone and H2O, add Et3N, and react at 37°C for 5h to obtain 6-((tert-butoxycarbonyl)amino)hexanoic acid (D18);

[0033] Step 2): 6-((tert-butoxycarbonyl)amino)hexanoic acid obtained in step 1) was dissolved in EtOAc solution, cooled to 5°C, hydroxybenzotriazole and DCC were added, and the mixture was stirred at room temperature for 2 hours. Cyclohexylurea was precipitated by filtration, and the precipitate was washed with EA. Raw material D1 and triethylamine were added to the reaction mixture, and stirred for 3 hours to obtain tert-butyl (6-((5-hydroxypentyl)amino)-6-oxohexyl)carbamate (D21);

[0034] Step 3): tert-butyl (6-((5-hydroxypentyl)amino)-6-oxohexyl)carbamate obtained in step 2), raw material B4, The molecular sieves were dissolved in dry DCM, stirred at room temperature for 0.5 h, the temperature was lowered to 0°C, TMSOTf was added dropwise, and stirred at room temperature for 2 h to obtain tert-butyl (6-((5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)amino)-6-oxohexyl)carbamate (D22);

[0035] Step 4): Dissolve the tert-butyl (6-((5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)amino)-6-oxohexyl)carbamate obtained in step 3) in dichloromethane, add trifluoroacetic acid, and stir at room temperature for 1 hour to obtain 6-amino-N-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)hexanamide (D24);

[0036] Step 5): Oleanolic acid is dissolved in anhydrous dichloromethane, oxalyl chloride is slowly added dropwise at room temperature, stirred for 4 hours, the reaction solution is evaporated to dryness, toluene is added to dissolve and evaporated to dryness again, and the solvent is removed three times. The above solid product is dissolved in anhydrous DCM solution, 6-amino-N-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)hexanamide and triethylamine obtained in step 4) are added, and the mixture is stirred at room temperature for 4 hours to obtain oleanolic acid-28-acyl-(N-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)hexanamide) (F7);

[0037] Step 6): Dissolve the oleanolic acid-28-acyl-(N-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)hexanamide) obtained in step 5) in dry DCM / MeOH, add freshly prepared sodium methoxide:methanol solution, and stir at room temperature for 2h to obtain oleanolic acid-28-acyl-(N-(5-((β-D-glucose)oxy)pentyl)hexanamide) (L7).

[0038] The synthesis method of the oleanolic acid derivative immunoadjuvants L8 and L15 of the present invention is the same as that of L7. L8 is synthesized by replacing glucose trichloroacetimidate B4 with cellobiose trichloroacetimidate C4.

[0039] The synthetic route of the oleanolic acid derivative immunoadjuvant L6 of the present invention is as follows:

[0040]

[0041] The synthesis method of the oleanolic acid derivative immunoadjuvant L6 of the present invention comprises the following steps:

[0042] Step 1): Dissolve tert-butyl (6-((5-hydroxypentyl)amino)-6-oxohexyl)carbamate in dichloromethane, add trifluoroacetic acid, and stir at room temperature for 1 h to obtain 6-amino-N-(5-hydroxypentyl)hexanamide (D6);

[0043] Step 2): Oleanolic acid is dissolved in dry DCM, oxalyl chloride is slowly added dropwise at room temperature, the reaction solution is evaporated for 4 hours, toluene is added to dissolve and then evaporated, and the solvent is removed three times. The above solid product is dissolved in anhydrous DCM solution, 6-amino-N-(5-hydroxypentyl) hexanamide and triethylamine obtained in step 1) are added, and the reaction is carried out at room temperature to obtain oleanolic acid-28-acyl-(N-(5-hydroxypentyl) hexanamide) (L6).

[0044] The synthesis method of the oleanolic acid derivative immune adjuvants L14, L18 and L20 of the present invention is the same as that of L6.

[0045] The synthetic route of the oleanolic acid derivative immunoadjuvant L9 of the present invention is as follows:

[0046]

[0047] Step 1): dissolving the raw material L-Threonine in water, adding NaHCO3 and (Boc)2O in methanol solution, stirring at room temperature for 24 hours to obtain (tert-butyloxycarbonyl)-L-threonine (D26);

[0048] Step 2): The (tert-butyloxycarbonyl)-L-threonine obtained in step 1) was dissolved in an EtOAc solution, cooled to 5°C, hydroxybenzotriazole and DCC were added, and the mixture was stirred at room temperature for 2 h. Cyclohexylurea was filtered and precipitated, and the precipitate was washed with EA. The raw material D1 and triethylamine were added to the reaction mixture, and stirred for 3 h to obtain tert-butyl (1-((5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)amino)-3-hydroxy-1-oxobutan-2-yl)carbamate (D27);

[0049] Step 3): tert-butyl (1-((5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)amino)-3-hydroxy-1-oxobutan-2-yl)carbamate obtained in step 2), raw material B4, Molecular sieves were dissolved in dry DCM and added The mixture was stirred at room temperature for 20 min under the protection of N2, the temperature was lowered to -10°C, TMSOTf was added dropwise, and the mixture was stirred at -10°C for 40 min to obtain tert-butyl (3-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)-1-((5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)amino)-1-oxobutan-2-yl)carbamate (D28);

[0050] Step 4): Dissolve tert-butyl (3-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)-1-((5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)amino)-1-oxobutan-2-yl)carbamate obtained in step 3) in dichloromethane, add trifluoroacetic acid, and stir at room temperature for 1 hour to obtain 2-amino-3-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)-N-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)butanamide (D29);

[0051] Step 5): Oleanolic acid is dissolved in anhydrous dichloromethane, oxalyl chloride is slowly added dropwise at room temperature, stirred for 4 hours, the reaction solution is evaporated to dryness, toluene is added to dissolve and evaporated to dryness again, and the solvent is removed three times. The above solid product is dissolved in anhydrous DCM solution, 2-amino-3-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)-N-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)butyramide and triethylamine obtained in step 4) are added, and the mixture is stirred at room temperature for 4 hours to obtain 3-oxooleanolic acid-28-acyl-(3-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)-N-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)butyramide) (F9);

[0052] Step 6): The 3-oxooleanolic acid-28-acyl-(3-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)-N-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)butyramide) obtained in step 5) was dissolved in dry DCM / MeOH, and freshly prepared sodium methoxide:methanol solution was added and stirred at room temperature for 2 h to obtain oleanolic acid-28-acyl-(3-((β-D-glucose)oxy)-N-(5-((β-D-glucose)oxy)pentyl)butyramide) (L9).

[0053] The synthesis method of the oleanolic acid derivative immune adjuvant L16 of the present invention is the same as that of L9.

[0054] The synthetic route of the oleanolic acid derivative immunoadjuvant L21 of the present invention is as follows:

[0055]

[0056] Step 1): Dissolve the raw materials glucose trichloroacetimidate B4 and benzyl oleanolic acid A5 in anhydrous DCM and add molecular sieves, stirred at room temperature for 40 min under N2 conditions, TMSOTf was added dropwise, and the mixture was stirred for 20 min to obtain [3-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucose) oleanolic acid-28-yl]-benzyl ester (N2);

[0057] Step 2): dissolving the [3-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucose) oleanolic acid-28-yl]-benzyl ester obtained in step 1) in DCM / MeOH (V:V, 1:1), adding 10% Pd / C, and reacting at room temperature for 4 hours under 1atm H2 to obtain 3-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucose) oleanolic acid (N3);

[0058] Step 3): 3-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucose)oleanolic acid obtained in step 2) is dissolved in anhydrous dichloromethane, oxalyl chloride is slowly added dropwise at room temperature, stirred for 4 hours, the reaction solution is evaporated to dryness, toluene is added to dissolve and evaporated to dryness again, and the solvent is removed repeatedly three times. The above solid product is dissolved in anhydrous DCM solution, 5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentane-1-amine and triethylamine are added, and the mixture is stirred at room temperature for 4 hours to obtain 3-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucose)-oleanolic acid-28-acyl-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentane) (F21);

[0059] Step 4): The 3-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucose)-oleanolic acid-28-acyl-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentane) obtained in step 3) was dissolved in dry DCM / MeOH, and freshly prepared sodium methoxide:methanol solution was added, and stirred at room temperature for 2 h to obtain 3-O-(β-D-glucose)-oleanolic acid-28-acyl-(5-((β-D-glucose)oxy)pentane) (L21).

[0060] The synthesis method of the oleanolic acid derivative immune adjuvant L22 of the present invention is the same as that of L21.

[0061] The synthetic route of the oleanolic acid derivative immunoadjuvant L23 of the present invention is as follows:

[0062]

[0063] Step 1): Dissolve the raw materials of cellobiose trichloroacetimidate C4 and benzyl oleanolic acid A5 in anhydrous DCM and add molecular sieves, stirred at room temperature for 40 min under N2 conditions, TMSOTf was added dropwise, and the mixture was stirred for 20 min to obtain (3-O-(hepta-O-benzoyl-β-D-cellobiose) oleanolic acid-28-yl)-benzyl ester (F23);

[0064] Step 2): The (3-O-(hepta-O-benzoyl-β-D-cellobiose) oleanolic acid-28-yl)-benzyl ester obtained in step 1) was dissolved in dry DCM / MeOH, and freshly prepared sodium methoxide:methanol solution was added, and stirred at room temperature for 2 h to obtain (3-O-(β-D-cellobiose) oleanolic acid-28-yl)-benzyl ester (L23).

[0065] The synthesis method of the oleanolic acid derivative immune adjuvant L24 of the present invention is the same as that of L23. DETAILED DESCRIPTION

[0066] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the accompanying drawings and Examples. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the following examples are purchased from conventional biochemical reagents unless otherwise specified. BRIEF DESCRIPTION OF THE DRAWINGS

[0067] Figure 1-Figure 24 The nuclear magnetic resonance hydrogen spectrum of the oleanolic acid derivative immune adjuvant in the example.

[0068] Fig.25The data are the hemolytic test data of the final product, oleanolic acid derivative immune adjuvant, at a concentration of 500 μg / mL in the example.

[0069] The organic chemical method for synthesizing several types of oleanolic acid derivative immunoadjuvants is as follows:

[0070] Example 1 Synthesis of Oleanolic Acid-28-Acyl-Pentanol (L1)

[0071] Oleanolic acid-28-acyl-pentanol (L1): Oleanolic acid (0.500 g, 1.00 eq) was dissolved in dry DCM (3.000 mL), and oxalyl chloride (0.880 mL, 10.13 eq) was slowly added dropwise at room temperature. The mixture was stirred for 4 h, and the reaction solution was evaporated to dryness. Toluene was added to dissolve the mixture and then evaporated to dryness. The reaction was repeated three times to remove the solvent. The above solid product was dissolved in anhydrous DCM solution (3.000 mL), and amine raw material D1 (0.094 g, 1.00 eq) and 5 drops of triethylamine were added. The reaction was reacted at room temperature for 4 h. After the reaction was completed, the mixture was concentrated under reduced pressure, the reaction solution was evaporated to dryness to remove the solvent, and then dissolved in DCM and extracted with water for several times. The mixture was washed with saturated NaCl, dried over anhydrous Na2SO4, concentrated in vacuo, and purified by column chromatography (dichloromethane: methanol = 30:1) to obtain 0.463 g of an oily solid with a yield of 78.08%.

[0072]

[0073] 1 H NMR (400MHz, CDCl3) δ7.15(t,J=6.0Hz,1H),5.94(t,J=5.4Hz,1H),5.35(s,1H),4.61(dd,J=11.8,4 .2Hz,1H),3.61(td,J=6.4,3.2Hz,4H),3.35–3.31(m,2H),3.06–2.92(m,1H),2.48(d,J=9.5Hz,1H), 2.14(d,J=9.3Hz,1H),1.93–1.88(m,2H),1.72(d,J=13.6Hz,2H),1.62–1.54(m,9H),1.38–1,29(m, 14H),1.14(s,3H),1.04(d,J=7.3Hz,2H),0.94(d,J=1.9Hz,6H),0.88(d,J=2.7Hz,9H),0.75(s,3H). 13C NMR (101MHz, CDCl3) δ178.15,145.00,122.41,84.50,77.69,77.68–75.8 9(m),76.32–75.89(m),62.42,55.01,53.32,47.34,46.65,46.14,42.07, 39.26,37.89,36.74,34.02,34.01–31.53(m),30.62,29.10,27.88,27.1 6,25.82,25.60,23.97–22.45(m),18.04,16.66,15.32.HRMS(ESI):[M+H] + calculated:542.4568,found:542.4564.

[0074] Example 2 Synthesis of Oleanolic Acid-28-Acyl-(5-β-D-Glucose) Oxy) Pentane) (L2)

[0075] A: tert-butyl (5-hydroxypentyl)carbamate (D10): Add the raw material D1 (0.100 g, 1.00 eq) to (Boc)2O (0.254 g, 1.00 eq) and react at 80°C for 10 min. After the reaction is completed, concentrate under reduced pressure and purify by silica gel column chromatography (dichloromethane: methanol = 110: 1) to obtain 0.128 g of an oily substance with a yield of 65.3%.

[0076]

[0077] 1 H NMR (400MHz, CDCl3) δ4.60 (s, 1H), 3.62 (d, J = 5.5Hz, 2H), 3.10 (d, J = 6.4Hz, 2H), 1.5 6(d,J=7.8Hz,2H),1.48(d,J=7.2Hz,2H),1.42(s,9H),1.38(dd,J=6.6,3.5Hz,2H). 13 CNMR (101MHz, CDCl3) δ156.07,79.06,62.55,40.36,32.20,29.80,28.37,27.36,22.87.

[0078] B: tert-butyl (5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentyl)carbamate (D11): Glucose trichloroacetimidate B4 (6.000 g, 1.00 eq), raw material D10 (2.067 g, 1.00 eq), The molecular sieve was dissolved in dry DCM (30.000 mL), stirred at room temperature for 0.5 h, the temperature was lowered to 0°C, TMSOTf (0.111 mL, 0.060 eq) was slowly added dropwise, and stirring was continued at room temperature for 2 h. After the reaction was completed, triethylamine was added to quench, and the mixture was filtered through diatomaceous earth, concentrated under reduced pressure, and purified by column chromatography (ethyl acetate: petroleum ether = 1:3) to obtain 3.757 g of a thick product with a yield of 59.04%.

[0079]

[0080] 1 H NMR (400MHz, CDCl3) δ8.11–8.06(m,2H),7.99–7.91(m,4H),7.78–7.74(m,2H),7.59(dd,J=10.2,7.5Hz,2 H),7.44–7.33(m,8H),7.26(t,J=7.8Hz,2H),6.04(d,J=5.2Hz,1H),5.76(dd,J=2.9,1.1Hz,1H),5.50(d, J=8.8Hz,1H),4.77(dd,J=5.8,2.4Hz,1H),4.51(dd,J=12.1,2.9Hz,2H),4.37(dd,J=12.1,4.9Hz,1H),3. 38–3.30(m,1H),3.28–3.20(m,1H),3.06(d,J=6.1Hz,2H),1.56–1.49(m,2H),1.41(s,9H),1.28(ddd,4H). 13 C NMR (101MHz, CDCl3) δ166.12,133.19,129.75,128.78,128.47–128.12(m),101.26,77.32,77.00,76.68,72.85,71.90,69.79,63.14,28.39.

[0081] C: (2,3,4,6-Tetra-O-benzoyl-β-D-glucose)oxy)pentane-1-amine (D14): The raw material D11 (0.110 g, 1.00 eq) was dissolved in dichloromethane (3.000 mL), trifluoroacetic acid (0.112 mL) was added, and the mixture was stirred at room temperature for 1 h, then concentrated under reduced pressure, and purified by column chromatography (dichloromethane: methanol = 10:1) to obtain 0.097 g of an oily substance with a yield of 86.6%.

[0082]

[0083] 1H NMR (400MHz, CDCl3) δ8.01(d,J=7.4Hz,2H),7.92(dd,J=15.1,7.5Hz,4H),7.83(d,J=7.4Hz,2H),7.50(dt,J=8.1, 6.8Hz,3H),7.44–7.30(m,8H),7.28(s,1H),5.91(t,J=9.7Hz,1H),5.70(t,J=9.7Hz,1H),5.49(dd,J=9.6,8.0Hz, 1H),4.81(d,J=7.9Hz,1H),4.67(dd,J=12.1,3.0Hz,1H),4.49(dd,J=12.1,4.9Hz,1H),4.19–4.11(m,1H),3.87(d t,J=11.3,5.8Hz,1H),3.50(dt,J=9.7,6.1Hz,1H),2.65(s,2H),1.56–1.42(m,4H),1.22(dd,J=14.4,7.2Hz,2H). 13 C NMR (101MHz, CDCl3) δ166.26,165.77,165.20,133.43,133.19,129.73,129.44,129.08,128.75,12 8.36,101.22,77.32,77.00,76.68,72.79,72.17,71.95,69.63,62.97,39.51,28.39,26.83,22.61.

[0084] D: Oleanolic acid-28-acyl-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentane) (F2): Oleanolic acid (0.500 g, 1.00 eq) was dissolved in anhydrous dichloromethane (6.000 mL). Oxalyl chloride (0.880 mL, 10.13 eq) was slowly added dropwise at room temperature. The mixture was stirred for 4 h. The reaction solution was evaporated to dryness, toluene was added to dissolve it, and then evaporated to dryness again. This was repeated three times to remove all the solvent. The above solid product was dissolved in anhydrous DCM solution (6.000 mL), and raw material D14 (0.896 g, 1.20 eq) and triethylamine were added. The mixture was stirred at room temperature for 4 h. After the reaction was completed, the reaction solution was concentrated, dissolved in DCM, washed with water three times, washed with saturated NaCl, dried over anhydrous Na2SO4, concentrated, and purified by column chromatography (ethyl acetate: petroleum ether = 1:1) to obtain 0.933 g of a white solid with a yield of 63.47%.

[0085]

[0086] 1H NMR(400MHz,CDCl3)δ8.02(d,J=7.5Hz,2H),7.96(d,J=7.5Hz,2H),7.90(d,J=7.5Hz,2H),7.83(d,J=7.6Hz,2H),7.51(dt,J=13.2,7.5Hz,4H),7.40(d,J=3.2Hz,4H),7.33(d,J=7.7Hz,2H),7.27(d,J=6.4Hz,2H),6.99(t,J=5.6Hz,1H),5.90(t,J=9.6Hz,1H),5.69(d,J=9.7Hz,1H),5.55–5.49(m,1H),5.30(d,J=10.1Hz,1H),4.82(d,J=7.8Hz,1H),4.67–4.61(m,2H),4.50(dd,J=12.0,5.0Hz,1H),4.22–4.09(m,1H),3.92(dd,J=15.2,6.0Hz,1H),3.56–3.50(m,1H),3.06(d,J=6.4Hz,2H),2.83(d,J=9.9Hz,1H),2.03–1.71(m,8H),1.66(d,J=10.8Hz,4H),1.55(s,6H),1.47–1.29(m,8H),1.25(s,3H),1.15(s,3H),0.98–0.92(m,9H),0.89(s,6H),0.80(s,2H),0.76(s,1H). 13 C NMR(101MHz,CDCl3)δ176.79,165.04,157.65,144.94,133.17,129.73,128.74,128.31,101.27,84.61,77.32,77.00,76.68,72.86,72.14,70.00,69.80,63.19,60.41,55.08,53.37,47.40,46.18,42.00,39.32,37.91,36.80,34.06,32.93,30.66,28.88,27.94,25.65,23.53,23.26,20.71,16.87,16.56,15.40,14.14.

[0087] E: Oleanolic acid-28-acyl-(5-β-D-glucose)oxy)pentane) (L2): Raw material F2 (0.300 g, 1.00 eq) was dissolved in dry DCM / MeOH (1:2) (3.000 mL), and freshly prepared sodium methoxide:methanol (1 mol / L) solution (0.026 mL) was added. The mixture was stirred at room temperature for 2 h, and then acidic cation exchange resin was added to neutralize the pH to 7. The mixture was filtered, concentrated, and purified by column chromatography (dichloromethane:methanol = 20:1) to obtain 0.133 g of a white solid with a yield of 70.74%.

[0088]

[0089] 1 H NMR (400MHz, CDCl3) δ6.10(s,1H),5.37(s,1H),4.94(s,1H),4.78(s,1H),4.47(s,1H),4.29(d,J=7. 6Hz,1H),3.85(d,J=16.1Hz,3H),3.54(d,J=9.5Hz,2H),3.40–3.28(m,3H),3.20(dd,J=10.6,4.4Hz,1 H),3.02–2.91(m,1H),2.49(d,J=12.7Hz,2H),1.99–1.87(m,3H),1.78–1.68(m,2H),1.66–1.43(m,14 H),1.42–1.17(m,8H),1.15(s,3H),0.98(s,3H),0.91(s,3H),0.89(s,6H),0.78(s,3H),0.74(s,3H). 13 C NMR(101MHz, CDCl3)δ78.89,77.32,77.00,76.68,69.87,55.08,47.50,46.93–46.73(m),46.23,42.39–42.19(m),42.05,39.34,3 8.75,38.45,36.95,34.12,32.97,30.70,29.05,28.11,27.24,27.01,25.73,23.52,18.29,16.94,15.64,15.42.HRMS(ESI):[M+H] + calculated:704.5087,found:704.5096.

[0090] Example 3 Synthesis of Oleanolic Acid-28-Acyl-(N-(5-Hydroxypentyl) Hexanoamide) (L6)

[0091] A: tert-Butyl (6-((5-hydroxypentyl)amino)-6-oxohexyl)carbamate (D21): The raw material D18 (0.500 g, 1.00 eq) was dissolved in EtOAc ((5.000 mL)) solution, cooled to 5°C, hydroxybenzotriazole (0.245 g, 0.84 eq) and DCC (0.357 g, 0.80 eq) were added, and the mixture was stirred at room temperature for 2 h. The cyclohexylurea was precipitated by filtration and the precipitate was washed with EA. The raw material D1 (0.187 g, 0.84 eq) and triethylamine (0.370 mL) were added to the reaction mixture. After stirring for 3 h, the mixture was diluted with EtOAc, washed with 1N HCl, then with saturated sodium bicarbonate and water, filtered, concentrated, and purified by column chromatography (dichloromethane: methanol = 30:1) to obtain 0.466 g of the product with a yield of 68.5%.

[0092]

[0093] 1 H NMR (400MHz, CDCl3) δ6.23(s,1H),4.82(s,1H),3.57(t,J=6.3Hz,2H),3.19(dd,J=12.9,6.7Hz ,2H),3.07–3.02(m,2H),2.12(t,J=7.5Hz,2H),1.61–1.44(m,8H),1.39(s,9H),1.31(ddd,4H). 13 C NMR (101MHz, CDCl3) δ173.23,156.13,79.01,77.32,77.00,76.68,62.12,40.25,39.19,36.39,31.99,29.63,29.16,28.33,26.23,25.26,22.96.

[0094] B: Oleanolic acid-28-acyl-(N-(5-hydroxypentyl)hexanamide) (L6): Add raw material oleanolic acid (0.422g, 1.00eq) and amine raw material D6 (0.200g, 1.00eq). The synthesis method is the same as compound L1. Purification by column chromatography (dichloromethane: methanol = 7:1) to obtain 0.463g of oily solid, with a yield of 76.5%.

[0095]

[0096] 1H NMR (400MHz, CDCl3) δ5.33(d,J=14.4Hz,1H),4.64(s,1H),3.10(q,J=7.2Hz,6H),2.82(d,J=9.7Hz,1H),2.08–1.5 0(m,21H),1.40(t,J=7.3Hz,12H),1.25(s,3H),1.14(s,3H),0.92(dd,J=13.1,6.0Hz,12H),0.79(d,J=7.6Hz,3H). 13 C NMR (101MHz, CDCl3) δ174.26,168.23,154.68,134.02,127.41,104.98,77.32,77.00,76.68,69.78,62.26,54.79,55.28,48 .34,47.24,45.72,45.01,37.95,33.08,32.48,29.30,23.69–23.60(m),18.90,17.14,16.61,10.22,8.60.HRMS(ESI):[M+H] + calculated:655.5408,found:655.5381.

[0097] Example 43 Synthesis of 3-O-(β-D-glucose)-oleanolic acid-28-acyl-(5-((β-D-glucose)oxy)pentane) (L21)

[0098] A: [3-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucose) oleanolic acid-28-yl]-benzyl ester (N2): Dissolve the raw materials glucose trichloroacetimidate B4 (0.155 g, 1.15 eq) and oleanolic acid benzyl ester A5 (0.100 g, 1.00 eq) in anhydrous DCM (3.000 mL) and add The mixture was stirred at room temperature for 40 min under N2 conditions, TMSOTf (0.002 mL, 0.044 eq) was added dropwise, and the mixture was stirred for 20 min. After the reaction was completed, triethylamine was quenched, filtered through diatomaceous earth, concentrated under reduced pressure, and purified by column chromatography (ethyl acetate: petroleum ether = 1:5) to obtain 0.176 g of a white solid with a yield of 85.4%.

[0099]

[0100] 1H NMR (400MHz, CDCl3) δ8.03–8.00(m,2H),7.96–7.91(m,4H),7.86–7.80(m,2H),7.57–7.44(m,4H),7.38(ddd,8H),7.34–7.3 3(m,3H),7.29(d,J=8.0Hz,2H),5.92(t,J=9.7Hz,1H),5.63–5.55(m,2H),5.29(d,J=3.2Hz,1H),5.06(q,J=12.5Hz,2H),4. 86(d,J=7.9Hz,1H),4.63–4.52(m,2H),4.15(ddd,1H),3.10(dd,J=11.7,4.5Hz,1H),2.91(dd,J=13.6,3.8Hz,1H),1.70(dd d,6H),1.40–1.14(m,4H),1.09(s,3H),0.92(d,J=8.1Hz,7H),0.80(d,J=5.6Hz,3H),0.69(s,3H),0.63(s,3H),0.56(s,3H). 13 C NMR (101MHz, CDCl3) δ177.37,165.99,165.28,164.98,143.67,136.38,133.42,133.04,129.77,129. 40,128.78,128.47–128.07(m),127.91,122.47,103.28,90.75,77.32,77.00,76.68,72.95,72.04,70 .27,65.90,63.41,55.42,47.52,46.69,45.90,41.59,41.34,39.22,38.70,36.57,33.84,33.10,32.35,31.85,30.69,29.47,27.63,26.89,25.82,23.63,23.32,22.99,18.03,16.79,16.15,15.13,14.09.

[0101] B: 3-O-(2,3,4,6-Tetra-O-benzoyl-β-D-glucose)oleanolic acid (N3): The raw material N2 (0.114 g, 1.00 eq) was dissolved in DCM / MeOH (V:V, 1:1) (3.000 mL), 10% Pd / C (0.013 g) was added, and the mixture was reacted at room temperature for 4 h under 1 atm H2. After the reaction, it was filtered with diatomaceous earth, concentrated under reduced pressure, and purified by column chromatography (ethyl acetate: petroleum ether = 1:3) to obtain 0.090 g of a white solid with a yield of 85.71%.

[0102]

[0103] 1 H NMR(400MHz, CDCl3)δ8.19(d,J=7.5Hz,1H),8.08–7.86(m,7H),7.58–7.47(m,4H),7.44–7.27(m,8H),6.62( d,J=3.6Hz,1H),5.78(ddd,J=25.7,19.6,9.7Hz,2H),5.33(d,J=3.3Hz,1H),4.71–4.41(m,3H),4.26(dd,J=9 .8,3.7Hz,1H),3.21(d,J=6.2Hz,1H),2.82(d,J=10.7Hz,1H),1.87(s,5H),1.65–1.50(m,9H),1.34(dd,J=37 .3,24.1Hz,6H),1.13(s,3H),1.06(s,2H),0.98(s,3H),0.92(s,3H),0.90(s,6H),0.77(s,3H),0.74(s,3H). 13 C NMR (101MHz, CDCl3) δ183.83,143.58,133.06,129.74,128.27,122.61,79. 03,77.32,77.00,76.68,55.20,47.61,45.86,41.56,40.92,39.25,38.73,3 4.66,33.78,33.05,31.58,30.65,29.05,28.07,27.66,26.90,25.93,23.56 ,22.62,20.43,17.11,15.52,15.29,14.30,14.10,11.41.HRMS(ESI):[M+H] + calculated:1035.5253,found:1035.5259.

[0104] C: 3-O-(2,3,4,6-Tetra-O-benzoyl-β-D-glucose)-oleanolic acid-28-acyl-(5-((2,3,4,6-tetra-O-benzoyl-β-D-glucose)oxy)pentane) (F21): Add raw material N3 (0.051 g, 1.00 eq) and raw material D14 (0.028 g, 1.00 eq). The synthesis method is the same as compound F2. Purify by column chromatography (ethyl acetate: petroleum ether = 1:4) to obtain 0.069 g of white solid with a yield of 82.14%.

[0105]

[0106] 1 H NMR(400MHz,CDCl3)δ8.03–7.99(m,4H),7.96–7.88(m,8H),7.83(d,J=8.2Hz,4H),7.51(ddd,6H),7.41(s,2H),7.37-7.33(m,8H),7.30(s,2H),5.90(td,J=9.7,6.6Hz,2H),5.82(t,J=5.4Hz,1H),5.67(t,J=9.7Hz,1H),5.58(dt,J=10.2,8.9Hz,2H),5.50(dd,J=9.7,7.9Hz,1H),5.35(s,1H),4.84(dd,J=16.1,7.9Hz,2H),4.66–4.57(m,2H),4.57–4.47(m,2H),4.17–4.15(m,1H),3.89(dt,J=9.7,6.2Hz,1H),3.53(dt,J=9.5,6.4Hz,1H),3.15–3.05(m,2H),2.81(dd,J=16.2,10.0Hz,1H),2.49(d,J=9.4Hz,1H),1.63(dd,J=9.4,5.4Hz,5H),1.57–1.51(m,6H),1.15(dd,J=10.9,4.5Hz,6H),1.11(s,2H),0.97(d,J=6.6Hz,4H),0.91–0.89(m,7H),0.88(s,3H),0.87(s,3H),0.87(s,3H),0.86(s,3H),0.85(s,6H),0.84(s,2H),0.83(s,3H),0.69(s,2H),0.67(s,2H),0.63(s,2H). 13 C NMR(101MHz,CDCl3)δ177.91,165.86,165.01,133.20,129.77,128.78,128.31,101.27,77.32,77.00,76.68,72.88,72.05,70.39–70.20(m),69.91,55.32,39.28,34.57,31.57,30.71,28.98,27.65,26.89,25.68,25.26,23.26,22.61,21.02,20.42,19.41,18.73,16.84,15.22,14.39–13.99(m),11.40.

[0107] D: 3-O-(β-D-glucose)-oleanolic acid-28-acyl-(5-((β-D-glucose)oxy)pentane) (L21): Add raw material F21 (0.690 g, 1.00 eq) and freshly prepared sodium methoxide:methanol (1 mol / L) solution (0.012 mL). The synthesis method is the same as compound L2. Purify by column chromatography (dichloromethane:methanol=7:1) to obtain 0.025 g of white solid with a yield of 71.43%.

[0108]

[0109] 1 H NMR(400MHz,MeOD)δ5.26(s,1H),4.28–4.25(m,2H),3.96–3.92(m,2H),3.91–3.85(m,4H),3.68 (dd,J=11.8,5.1Hz,4H),3.58(dd,J=8.0,5.0Hz,2H),3.36(d,J=4.3Hz,3H),3.28(s,3H),3.21– 3.17(m,4H),2.90–2.82(m,1H),1.92(d,J=7.2Hz,2H),1.74–1.58(m,17H),1.45(dt,J=8.7,6.9 Hz,8H),1.18(s,3H),1.08(s,3H),0.97(d,J=4.8Hz,6H),0.93(s,3H),0.87(s,3H),0.83(s,3H). 13 C NMR(101MHz,MeOD)δ103.96,79.05,78.72,78.40,77.71,74.69,74.33,71.28,70.30,62.50,49.64,49.32,49.00,48.79,4 8.57,48.36,42.59,40.46,40.05,37.59,33.50,30.47,30.13,29.91,29.20,28.54,28.20,24.27,23.95.HRMS(ESI):[M+H] + calculated:866.5624,found:866.5679.

[0110] Example 5 (3-O-(β-D-cellobiose) oleanolic acid-28-yl)-benzyl ester (L23)

[0111] A: (3-O-(hepta-O-benzoyl-β-D-cellobiose)oleanolic acid-28-yl)-benzyl ester (F23): Cellobiose trichloroacetimidate C4 (2.560 g, 1.15 eq) and oleanolic acid benzyl ester A5 (1.000 g, 1.00 eq) were added as raw materials. The synthesis method was the same as compound N2. The product was purified by column chromatography (ethyl acetate: petroleum ether = 1:4) to obtain 2.676 g of a white solid with a yield of 79.4%.

[0112]

[0113] 1 H NMR(400MHz, CDCl3)δ8.00(d,J=7.2Hz,2H),7.96–7.90(m,4H),7.86–7.81(m,4H),7.73(dd, J=12.4,7.3Hz,4H),7.58(t,J=7.4Hz,1H),7.50(t,J=7.4Hz,1H),7.43–7.41(m,7H),7.39–7. 27(m,13H),7.20(dd,J=16.6,8.0Hz,4H),6.01(d,J=2.8Hz,1H),5.90(dd,J=17.7,7.5Hz,2H) ,5.70(t,J=9.7Hz,1H),5.62(dd,J=9.7,8.2Hz,1H),5.26(s,1H),5.13(d,J=8.0Hz,1H),5.07 (t,J=10.5Hz,2H),4.65–4.57(m,2H),4.49(dd,J=12.1,5.2Hz,1H),4.18–4.11(m,1H),4.07– 3.99(m,3H),3.67(d,J=9.1Hz,1H),3.18–3.10(m,1H),2.89(dd,J=13.5,3.7Hz,1H),2.00–1. 74(m,4H),1.67(dd,J=22.8,9.1Hz,3H),1.30–1.12(m,4H),1.09(s,3H),1.07–0.92(m,4H),0 .91(s,3H),0.89(d,J=2.5Hz,6H),0.82(s,3H),0.79(s,3H),0.72–0.62(m,2H),0.57(s,3H). 13C NMR (101MHz, CDCl3) δ166.03,165.72,164.68,163.64,143.56,137.53,136.35,133.34,132.82,129 .93–129.29(m),128.73,128.48–127.72(m),126.29,122.47,122.00,102.36,97.28,91.83,81.44, 77.32,77.00,76.68,73.01,72.31,71.69,69.56,67.51,65.89,55.53,47.42,46.69,45.81,41.64,41.31,39.20,38.50,36.63,35.37,33.81,33.06,30.64,28.24,26.87,25.86,23.59,16.72,15.19.

[0114] B: (3-O-(β-D-cellobiose)oleanolic acid-28-yl)-benzyl ester (L23): Add raw material F23 (0.500 g, 1.00 eq) and freshly prepared sodium methoxide:methanol (1 mol / L) solution (0.281 mL). The synthesis method is the same as compound L2. Purify by column chromatography (dichloromethane:methanol=7:1) to obtain 0.167 g of white solid with a yield of 61.40%.

[0115]

[0116] 1 H NMR (400MHz, CDCl3) δ7.47–7.32(m,5H),5.68(s,1H),5.36(d,J=9.4Hz,1H),5.27(s ,1H),5.15–4.93(m,2H),4.81(d,J=6.8Hz,1H),4.45(s,1H),4.30–3.88(m,3H),3.63 (dd,J=26.8,21.5Hz,2H),3.47–3.05(m,4H),2.87(s,2H),2.09–1.37(m,10H),1.36 –1.17(m,10H),1.16–0.96(m,6H),0.94–0.74(m,9H),0.61(dd,J=24.0,20.2Hz,6H). 13C NMR(101MHz,DMSO)δ165.89,149.16,140.13,143.73,140.90,137.91,134.88,133.00,131.07,125.19, 120.61,114.75,111.30,97.87,97.63,94.96,82.74,81.73,81.46,59.01,58.27,53.43,52.49,51.60, 49.31-42.60(m),40.13,39.92,39.60,39.33–38.87(m),38.87–38.56(m).36.49,35.30,34.57,33.11, 31.93,27.58,26.87,26.31,24.05-22.06(m),20.74-19.24(m),14.01,13.34,12.94.HRMS(ESI):[M+H] + calculated:871.5202,found:871.5231.

[0117] The preparation of oleanolic acid derivative immunoadjuvants L10, L17, and L19 is the same as that of L1. The preparation of L3, L4, L5, L7, L8, L9, L11, L12, L13, L15, and L16 is the same as that of L2. The preparation of L14, L18, and L20 is the same as that of L6. The preparation of L22 is the same as that of L21. The preparation of L24 is the same as that of L23.

[0118] The hemolytic effect of compounds L1-L24 can be identified by the following method:

[0119] The single wells of the Falcon flexible round-bottom 96-well plate were numbered, and then 120 μL of PBS suspensions of QS-21 and saponin analogs L1-L24 with a series of gradient concentrations were added to the single wells of the well plate, and each group was repeated 3 times. 30 μL of 10% red blood cell suspension was added to the single well of the saponin solution and gently mixed. After incubation in a 37°C incubator for 1 hour, the cells were taken out and centrifuged at 3000 r / min for 10 minutes. The supernatant was aspirated and the absorbance value was measured at 575 nm using an ELISA reader. The hemolysis rate was calculated according to the formula: hemolysis rate (%) = (OD-OD negative) / (OD positive-OD negative) × 100%. OD is the absorbance of the experimental group; OD negative is the absorbance of the negative control group; OD positive is the absorbance of the positive control group. As shown in Table 1, the hemolysis rate of oleanolic acid derivative immune adjuvants at a concentration of 500 μg / mL.

[0120] Four groups were set up in the experiment, namely the treatment group (prepared 30 μL erythrocyte suspension plus 120 μL QS-21 and analogs), the positive control group (prepared 30 μL erythrocyte suspension plus 120 μL Triton X-100 suspension), the negative control group (prepared 30 μL erythrocyte suspension plus 120 μL PBS / DMSO (9:1) suspension) and the blank control group (30 μL physiological saline plus 120 μL PBS / DMSO (9:1) suspension), and the absorbance was measured at 575 nm. Each group was repeated 3 times.

[0121] The saponin analogue is a kind of oleanolic acid derivative immune adjuvant.

[0122] The application of the oleanolic acid derivative immune adjuvant is as follows:

[0123] As can be seen from Table 1, after incubation for 1 h, QS-21 and oleanolic acid derivatives L1-L24 at various concentration gradients were observed, and it was found that QS-21 saponin showed obvious complete hemolysis at each concentration gradient, while hemolysis was not observed for some compounds in the oleanolic acid derivatives. Only compounds L11, L12, L13, L15, L18, and L20 showed hemolysis at concentrations of 500 μg / mL and 250 μg / mL, among which compounds L13 and L18 showed hemolysis at each gradient.

[0124] The above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not possible to list all the embodiments here. Any obvious changes or modifications derived from the technical solution of the present invention are still within the scope of protection of the present invention.

Claims

1. Oleanolic acid derivatives immunoadjuvants, whose structural characteristics are the following oleanolic acid derivatives of the general formula 1-1, 1-2, 1-3: in, R 1 It can be a monosaccharide, a disaccharide, a trisaccharide or a derivative thereof; R 3 is H, hydroxyl, amino, fluorine atom or substituted hydroxyamino, etc.; R 2 is benzyloxy, phenoxy or substituted benzyloxy and substituted phenoxy or an acyl side chain as shown in the following structure: Among them, the alkyl group (CH 2 ) n n=1-10, X can be O, NH; R 4 and R 5 It can be H, monosaccharide, disaccharide, or trisaccharide.

2. A chemical synthesis method of oleanolic acid derivatives according to claim 1, It is characterized in that The following steps are involved: Oleanolic acid was used as a raw material, and a carbonyl group and an oxime functional group were introduced at the C3 position, and a hydroxyl group was introduced at the C2 position to obtain oleanolic acid derivatives.

3. The chemical synthesis method of the oleanolic acid derivative according to claim 1, It is characterized in that The method involves full protection of the hydroxyl groups of glucose, cellobiose or maltotriose, wherein the protecting group is selected from acetyl group or benzoyl group.

4. The chemical synthesis method of the oleanolic acid derivative according to claim 1, It is characterized in that The following steps are involved: The intermediate product is subjected to debenzoylation and acetyl protection reaction, and purified to obtain the final product, an oleanolic acid derivative.

5. The chemical synthesis method of the final product oleanolic acid derivative immunoadjuvant according to claim 4, It is characterized in that The specific steps are: the glycosylation intermediate product is dissolved in dry dichloromethane / methanol, a freshly prepared sodium methoxide:methanol solution is added, stirred at room temperature for 2 hours, then an acidic cation exchange resin is added to neutralize the pH to 7, filtered, concentrated, and purified by column chromatography to obtain the final product, an oleanolic acid derivative.

6. The chemical synthesis method of the final product oleanolic acid derivative immunoadjuvant according to claim 5, It is characterized in that The volume ratio of solvent dichloromethane / methanol is 1:2, and the concentration of freshly prepared sodium methoxide:methanol solution is 1 mol / L.